Analysts See $-0.25 EPS for INSYS Therapeutics, Inc. (INSY)

July 12, 2018 - By Michael Collier

Investors sentiment decreased to 0.75 in Q1 2018. Its down 0.01, from 0.76 in 2017Q4. It worsened, as 14 investors sold INSYS Therapeutics, Inc. shares while 30 reduced holdings. 11 funds opened positions while 22 raised stakes. 12.41 million shares or 24.49% less from 16.43 million shares in 2017Q4 were reported.
Northern Corporation reported 316,325 shares. Prelude Mgmt Limited Company holds 840 shares. 4,830 were accumulated by Zurcher Kantonalbank (Zurich Cantonalbank). Meeder Asset Mgmt owns 162 shares. Jpmorgan Chase And Company, a New York-based fund reported 25,624 shares. Fmr Ltd Company reported 242,764 shares. 86,520 were reported by Alliancebernstein Limited Partnership. Moreover, Reilly Financial Advisors Lc has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Architects has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Pnc Service Gru Inc Inc has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Great West Life Assurance Company Can has 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY). Deutsche Natl Bank Ag holds 76,616 shares. Parametric Assoc Ltd Liability Corporation invested in 19,493 shares. California State Teachers Retirement System owns 37,129 shares. Shell Asset Mgmt Com has 0.01% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY).

Since February 21, 2018, it had 0 insider purchases, and 1 insider sale for $1.07 million activity.

Analysts expect INSYS Therapeutics, Inc. (NASDAQ:INSY) to report $-0.25 EPS on August, 2.They anticipate $0.24 EPS change or 2,400.00 % from last quarter’s $-0.01 EPS. After having $-0.22 EPS previously, INSYS Therapeutics, Inc.’s analysts see 13.64 % EPS growth. The stock increased 0.53% or $0.04 during the last trading session, reaching $7.65. About 311,296 shares traded. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 47.95% since July 12, 2017 and is downtrending. It has underperformed by 60.52% the S&P500.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $564.64 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: Fool.com which released: “3 Biotech Stocks With Major Potential Catalysts in July” on June 27, 2018, also Benzinga.com with their article: “Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates” published on July 01, 2018, Nasdaq.com published: “INSYS Therapeutics Provides an Update on Its Ongoing Transformation” on June 18, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: Benzinga.com and their article: “5 Hot Pot Stocks In 2018 And 5 More To Watch The Rest Of The Year” published on July 10, 2018 as well as Investorplace.com‘s news article titled: “4 Drug and Biotech Stocks Awaiting FDA Decisions in July” with publication date: July 02, 2018.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>